We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen Submits Denosumab BLA for Cancer Bone Metastases
Amgen Submits Denosumab BLA for Cancer Bone Metastases
May 14, 2010
Amgen has submitted a second BLA for its RANK ligand inhibitor denosumab, this time for the reduction of skeletal related events due to bone metastases, the spread of tumors to the skeleton.